Explore › Intervention › Statins
Intervention

Statins

Also known as: 3-Hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor 3-Hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor (substance) 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor (substance) 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor product Clinician prescribing of statins for ASCVD patients who have intellectual/developmental disabilities HMG COA REDUCTASE INHIB HMG COA reductase inhibitor HMG CoA Reductase Inhibitor HMG CoA Reductase Inhibitors HMG-CoA Reductase Inhibitor +39 more
3 findings 1 paper 3 related entities View in graph →

Related entities

conditions
Atherosclerotic cardiovascular disease risk estimator plus1
outcomes
Statin therapy1
studys
PMC80096951

Findings (27)

None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for statins compared to non-IDD patients (47.9% vs 58.7%), r

Effect: decline; adjusted OR 0.73; CI: 95% CI = 0.67-0.8

Size: adjusted OR 0.73 CI: 95% CI = 0.67-0.8
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for statins compared to non-IDD patients (47.9% vs 58.7%), r

Effect: decline; adjusted OR 0.73; CI: 95% CI = 0.67-0.8

Size: adjusted OR 0.73 CI: 95% CI = 0.67-0.8
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for statins compared to non-IDD patients (47.9% vs 58.7%), r

Effect: decline; adjusted OR 0.73; CI: 95% CI = 0.67-0.8

Size: adjusted OR 0.73 CI: 95% CI = 0.67-0.8
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for statins compared to non-IDD patients (47.9% vs 58.7%), r

Effect: decline; adjusted OR 0.73; CI: 95% CI = 0.67-0.8

Size: adjusted OR 0.73 CI: 95% CI = 0.67-0.8
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for statins compared to non-IDD patients (47.9% vs 58.7%), r

Effect: decline; adjusted OR 0.73; CI: 95% CI = 0.67-0.8

Size: adjusted OR 0.73 CI: 95% CI = 0.67-0.8
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for statins compared to non-IDD patients (47.9% vs 58.7%), r

Effect: decline; adjusted OR 0.73; CI: 95% CI = 0.67-0.8

Size: adjusted OR 0.73 CI: 95% CI = 0.67-0.8
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for statins compared to non-IDD patients (47.9% vs 58.7%), r

Effect: decline; adjusted OR 0.73; CI: 95% CI = 0.67-0.8

Size: adjusted OR 0.73 CI: 95% CI = 0.67-0.8
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for statins compared to non-IDD patients (47.9% vs 58.7%), r

Effect: decline; adjusted OR 0.73; CI: 95% CI = 0.67-0.8

Size: adjusted OR 0.73 CI: 95% CI = 0.67-0.8
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for statins compared to non-IDD patients (47.9% vs 58.7%), r

Effect: decline; adjusted OR 0.73; CI: 95% CI = 0.67-0.8

Size: adjusted OR 0.73 CI: 95% CI = 0.67-0.8
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for statins compared to non-IDD patients (47.9% vs 58.7%), r

Effect: decline; adjusted OR 0.73; CI: 95% CI = 0.67-0.8

Size: adjusted OR 0.73 CI: 95% CI = 0.67-0.8
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for statins compared to non-IDD patients (47.9% vs 58.7%), r

Effect: decline; adjusted OR 0.73; CI: 95% CI = 0.67-0.8

Size: adjusted OR 0.73 CI: 95% CI = 0.67-0.8
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for statins compared to non-IDD patients (47.9% vs 58.7%), r

Effect: decline; adjusted OR 0.73; CI: 95% CI = 0.67-0.8

Size: adjusted OR 0.73 CI: 95% CI = 0.67-0.8
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for statins compared to non-IDD patients (47.9% vs 58.7%), r

Effect: decline; adjusted OR 0.73; CI: 95% CI = 0.67-0.8

Size: adjusted OR 0.73 CI: 95% CI = 0.67-0.8
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for statins compared to non-IDD patients (47.9% vs 58.7%), r

Effect: decline; adjusted OR 0.73; CI: 95% CI = 0.67-0.8

Size: adjusted OR 0.73 CI: 95% CI = 0.67-0.8
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for statins compared to non-IDD patients (47.9% vs 58.7%), r

Effect: decline; adjusted OR 0.73; CI: 95% CI = 0.67-0.8

Size: adjusted OR 0.73 CI: 95% CI = 0.67-0.8
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for statins compared to non-IDD patients (47.9% vs 58.7%), r

Effect: decline; adjusted OR 0.73; CI: 95% CI = 0.67-0.8

Size: adjusted OR 0.73 CI: 95% CI = 0.67-0.8
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for statins compared to non-IDD patients (47.9% vs 58.7%), r

Effect: decline; adjusted OR 0.73; CI: 95% CI = 0.67-0.8

Size: adjusted OR 0.73 CI: 95% CI = 0.67-0.8
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for statins compared to non-IDD patients (47.9% vs 58.7%), r

Effect: decline; adjusted OR 0.73; CI: 95% CI = 0.67-0.8

Size: adjusted OR 0.73 CI: 95% CI = 0.67-0.8
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for statins compared to non-IDD patients (47.9% vs 58.7%), r

Effect: decline; adjusted OR 0.73; CI: 95% CI = 0.67-0.8

Size: adjusted OR 0.73 CI: 95% CI = 0.67-0.8
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for statins compared to non-IDD patients (47.9% vs 58.7%), r

Effect: decline; adjusted OR 0.73; CI: 95% CI = 0.67-0.8

Size: adjusted OR 0.73 CI: 95% CI = 0.67-0.8
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for statins compared to non-IDD patients (47.9% vs 58.7%), r

Effect: decline; adjusted OR 0.73; CI: 95% CI = 0.67-0.8

Size: adjusted OR 0.73 CI: 95% CI = 0.67-0.8
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for statins compared to non-IDD patients (47.9% vs 58.7%), r

Effect: decline; adjusted OR 0.73; CI: 95% CI = 0.67-0.8

Size: adjusted OR 0.73 CI: 95% CI = 0.67-0.8
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for statins compared to non-IDD patients (47.9% vs 58.7%), r

Effect: decline; adjusted OR 0.73; CI: 95% CI = 0.67-0.8

Size: adjusted OR 0.73 CI: 95% CI = 0.67-0.8
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for statins compared to non-IDD patients (47.9% vs 58.7%), r

Effect: decline; adjusted OR 0.73; CI: 95% CI = 0.67-0.8

Size: adjusted OR 0.73 CI: 95% CI = 0.67-0.8
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for statins compared to non-IDD patients (47.9% vs 58.7%), r

Effect: decline; adjusted OR 0.73; CI: 95% CI = 0.67-0.8

Size: adjusted OR 0.73 CI: 95% CI = 0.67-0.8
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for statins compared to non-IDD patients (47.9% vs 58.7%), r

Effect: decline; adjusted OR 0.73; CI: 95% CI = 0.67-0.8

Size: adjusted OR 0.73 CI: 95% CI = 0.67-0.8
PMC8009695
Finding details → · Paper → · Graph →
None
decline

Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for statins compared to non-IDD patients (47.9% vs 58.7%), r

Effect: decline; adjusted OR 0.73; CI: 95% CI = 0.67-0.8

Size: adjusted OR 0.73 CI: 95% CI = 0.67-0.8
PMC8009695
Finding details → · Paper → · Graph →

Papers (1)